These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 3882571)

  • 1. Selective antilymphocyte sera (SAL) in bone marrow transplantation. I. In vitro characterization of antihuman SAL and the development of absorption procedures using cultured cell lines.
    Anderson MJ; Schmitz N; Müller-Hermelink HK; Müller-Ruchholtz W
    Int Arch Allergy Appl Immunol; 1985; 76(3):218-25. PubMed ID: 3882571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study.
    Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH
    J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antilymphocytic antibodies and marrow transplantation. VI. Absence of immunosuppression in vivo after injection of monoclonal antibodies blocking graft-versus-host reactions and humoral antibody formation in vitro.
    Thierfelder S; Hoffmann-Fezer G; Rodt H; Doxiadis I; Eulitz M; Kummer U
    Transplantation; 1983 Mar; 35(3):249-54. PubMed ID: 6340277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic bone marrow transplantation: relation between chimaerism and immunity.
    Vossen J
    Verh K Acad Geneeskd Belg; 1998; 60(2):111-43; discussion 143-5. PubMed ID: 9703764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An attempt at isolation and partial characterization of specific antibodies from antithymocyte serum.
    Fricová V; Hrubá A; Paluska E; Holdová J
    Folia Biol (Praha); 1979; 25(6):353-61. PubMed ID: 42567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
    Li JM; Waller EK
    Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early vaccination with tumor-lysate-pulsed dendritic cells after allogeneic bone marrow transplantation has antitumor effects.
    Moyer JS; Maine G; Mulé JJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1010-9. PubMed ID: 17084367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous protection against allograft rejection and graft-versus-host disease after total lymphoid irradiation: role of natural killer T cells.
    Liu YP; Li Z; Nador RG; Strober S
    Transplantation; 2008 Feb; 85(4):607-14. PubMed ID: 18347541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation.
    Hossain MS; Roback JD; Lezhava L; Hillyer CD; Waller EK
    Biol Blood Marrow Transplant; 2005 Mar; 11(3):169-80. PubMed ID: 15744235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous superantigens in allogeneic bone marrow transplant recipients rapidly and selectively expand donor T cells which can produce IFN-gamma.
    Jones MS; Riley R; Hamilton BL; Paupe J; Perez D; Levy RB
    Bone Marrow Transplant; 1994 Nov; 14(5):725-35. PubMed ID: 7889005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow transplantation in inbred strains of mice. I. The failure of development of normal T cell function following allogeneic transplantation.
    Trier L; Rubin B
    Acta Pathol Microbiol Scand B Microbiol Immunol; 1974 Oct; 82B(5):724-32. PubMed ID: 4139875
    [No Abstract]   [Full Text] [Related]  

  • 16. Patterns of antibody reactivity against selected human leukemia cell lines.
    Anderson MJ; Oeljeschlager H; Müller-Hermelink HK; Müller-Ruchholtz W
    J Cancer Res Clin Oncol; 1981; 101(1):101-7. PubMed ID: 7024284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of immune reactions by antilymphocyte serum.
    Müller-Ruchholtz W; Wottge HU; Müller-Hermelink HK
    Transplant Proc; 1978 Mar; 10(1):23-9. PubMed ID: 24907
    [No Abstract]   [Full Text] [Related]  

  • 18. [Prevention of the graft vs host reaction in rats by means of allogeneic antilymphocyte serum following bone marrow transplantation].
    Jeannet M; Vaucher A; Gervasoni C
    Schweiz Med Wochenschr; 1972 Nov; 102(44):1598-600. PubMed ID: 4405059
    [No Abstract]   [Full Text] [Related]  

  • 19. OKT3 incubation of donor marrow for prophylaxis of acute graft-vs.-host disease (GvHD) in allogeneic bone marrow transplantation.
    Prentice HG
    J Clin Immunol; 1982 Jul; 2(3 Suppl):148S-153S. PubMed ID: 6290527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
    Johnson BD; Drobyski WR; Truitt RL
    Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.